AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06102031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDS-Guided
Description: ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading \<36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading \<20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization.
Study NCT06095518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DIC markers and Thrombin Generation Parameters
Description: Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
Study NCT05317377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Structured exercises focused on hand functionality
Study NCT05317377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Based Exergame
Description: Appropriate games from Leap Motion Based Exergame system focused on hand functionality
Study NCT06102031 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
Study NCT03935464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUMA
Description: Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
Study NCT06453018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional device, Rematee Bumper Belt or Night Shift
Description: Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention
Study NCT05524285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Support Catheter
Description: Endovascular procedure using the intracranial support catheter which approved by NMPA
Study NCT05524285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guide Catheter
Description: Endovascular procedure using the guide catheter which approved by NMPA
Study NCT05781841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of SOCS3 gene
Description: Detection of expression of SOCS3, in each samples using Real-Time PCR
Study NCT05781841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of IFN-α gene
Description: Detection of expression of IFN-α gene in each samples using Real-Time PCR
Study NCT05781841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of IFN-β gene
Description: Detection of expression of IFN-β gene in each samples using Real-Time PCR
Study NCT04760288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.
Study NCT04760288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.
Study NCT04760288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
Study NCT05615662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
Study NCT05615662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
Study NCT05950022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic tenotomy surgery of the iliopsoas tendon
Description: The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
Study NCT05245084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386(3)
Description: QD, PO
Study NCT05245084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: QD, PO
Study NCT05436145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study behavioral change mobile notification
Description: The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
Study NCT05533645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
Study NCT06483269 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PRP infiltration
Description: a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations.
Study NCT05918419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: PD-1 antibody
Study NCT04735770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine
Description: Postoperative pain management
Study NCT04735770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine
Description: Postoperative pain management
Study NCT05651308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care coordination delivered based on perceived need
Description: If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
Study NCT05651308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care coordination delivered based on usual care (e.g. discharge from hospital)
Description: If a patient is discharged from a hospital, the patient will be selected for care management services.
Study NCT05587868 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
Study NCT04840420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: social prescribing
Description: as above
Study NCT04840420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: as above
Study NCT05720026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYSA1901
Description: loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
Study NCT05720026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
Study NCT05720026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
Study NCT05720026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
Study NCT05720026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV, q3w/cycle, total 4cycle
Study NCT05720026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV, q3w/cycle, total 4cycle
Study NCT05426213 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Robot-assisted Bronchoscopy (Monarch Platform)
Description: Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
Study NCT05450926 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound-guided selective cervical nerve root block
Description: The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
Study NCT05450926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided selective cervical nerve root block
Description: The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
Study NCT05368415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
Study NCT05718323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
Study NCT03616067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox® injection
Description: Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
Study NCT03616067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopoderm® patches arm
Description: Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
Study NCT05409313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBP training
Description: The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.
Study NCT05409313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDM training
Description: A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
Study NCT05409313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SDM training
Description: A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
Study NCT05213013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask
Description: The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~* For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~* The child should be in an upright sitting position during nebulization.~* During the procedure, normal breathing should be given into the mask.~* As the medicine is finished, a sizzling sound is heard from the device.~* After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth.
Study NCT04455698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Telegenetic Counseling by Phone
Description: Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
Study NCT04455698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Telegenetic Counseling by Videoconferencing
Description: Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
Study NCT04455698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Arm
Description: Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
Study NCT05654272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Cardiac MRI
Study NCT05039177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally
Study NCT05039177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Administered orally
Study NCT05039177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered via intravenous infusion
Study NCT05039177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally
Study NCT05225233 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
Study NCT05225233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
Study NCT05769699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study NCT05857579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microblepharoexfoliation
Description: MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.
Study NCT05857579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulse light
Description: IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.
Study NCT05857579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian gland expression
Description: Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).
Study NCT05857579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Home-based therapy
Description: Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
Study NCT05857579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home-based therapy
Description: Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
Study NCT05645289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minodronate
Description: The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
Study NCT05645289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
Study NCT06286579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediately implant placement
Description: After atraumatic tooth extraction immediate implant placement with SOI surface and loading will be performed with temporary restoration. After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered
Study NCT06286579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed
Description: After atraumatic tooth extraction, the extraction site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place and immediate loadind with temporary restoration will be performed.~After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered